APTOAptose BiosciencesAPTO info
$0.40info-0.75%24h
Global rank35353
Market cap$3.15M
Change 7d-
YTD Performance-84.31%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Aptose Biosciences (APTO) Stock Overview

    Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

    APTO Stock Information

    Symbol
    APTO
    Address
    251 Consumers RoadToronto, ON M2J 4R3Canada
    Founded
    -
    Trading hours
    -
    Website
    https://www.aptose.com
    Country
    πŸ‡¨πŸ‡¦ Canada
    Phone Number
    647 479 9828

    Aptose Biosciences (APTO) Price Chart

    -
    Value:-

    Aptose Biosciences Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.397
    N/A
    Market Cap
    $3.15M
    N/A
    Shares Outstanding
    7.94M
    N/A
    Employees
    35.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org